Results 131 to 140 of about 12,211 (152)

Clinical relevance of serum natalizumab concentration and anti-natalizumab antibodies in multiple sclerosis

Multiple Sclerosis Journal, 2013
Eva Strijbis, Theo Rispens, Lisanne J Balk   +2 more
exaly  

Recurrence or rebound of clinical relapses after discontinuation of natalizumab therapy in highly active MS patients

Journal of Neurology, 2014
Thor Petersen, Nils Koch-Henriksen, Finn Sellebjerg   +2 more
exaly  

Natalizumab

Reactions Weekly, 2019
openaire   +1 more source

Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab

Multiple Sclerosis Journal, 2012
Gavin Giovannoni, Xavier Montalban, Per Soelberg Sørensen   +2 more
exaly  

Pregnancy and fetal outcomes following natalizumab exposure in pregnancy. A prospective, controlled observational study

Multiple Sclerosis Journal, 2015
Lilyana Amezcua, Kerstin Hellwig
exaly  

Pregnancy and natalizumab: results of an observational study in 35 accidental pregnancies during natalizumab treatment.

Multiple Sclerosis Journal, 2011
Ralf Gold, Kerstin Hellwig
exaly  

Natalizumab in Multiple Sclerosis: Long-Term Management

International Journal of Molecular Sciences, 2017
Carlo Alberto Artusi, Simona Rolla, Luca Durelli   +2 more
exaly  

Natalizumab treatment shows no clinically meaningful effects on immunization responses in patients with relapsing-remitting multiple sclerosis

Journal of the Neurological Sciences, 2014
Gabriel Pardo
exaly  

Multiple sclerosis associated fatigue during natalizumab treatment

Journal of the Neurological Sciences, 2009
Özgür Yaldızlı, Barbara Tettenborn, Norman Putzki   +2 more
exaly  

A review of the evidence for a natalizumab exit strategy for patients with multiple sclerosis

Autoimmunity Reviews, 2019
Paulus Stefan Rommer, Johann Sellner
exaly